10X Genomics Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
10X Genomics Inc (TXG)
10X Genomics Inc stock price live, this page displays NASDAQ TXG stock exchange data. View the TXG premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the 10X Genomics Inc real time stock price chart below.
What Is the 10X Genomics Inc Stock Price Today?
The 10X Genomics Inc stock price today is 12.27.
What Is the Stock Symbol for 10X Genomics Inc?
The stock symbol for 10X Genomics Inc is ""TXG.""
What Stock Exchange Does 10X Genomics Inc Trade On?
10X Genomics Inc is listed and trades on the NASDAQ stock exchange.
Is 10X Genomics Inc a Good Stock to Buy?
Determining whether 10X Genomics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TXG quote. (ISIN: US88025U1097)
What Is the 10X Genomics Inc Stock Price Today?
The 10X Genomics Inc stock price today is 12.27.
What Is the Stock Symbol for 10X Genomics Inc?
The stock symbol for 10X Genomics Inc is ""TXG.""
What Stock Exchange Does 10X Genomics Inc Trade On?
10X Genomics Inc is listed and trades on the NASDAQ stock exchange.
Is 10X Genomics Inc a Good Stock to Buy?
Determining whether 10X Genomics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TXG quote. (ISIN: US88025U1097)
12.27
-0.02(-0.16%)
Real-time Data·
Fair Value
An estimate of a 10X Genomics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.19
12.57
52 wk Range
6.78
24.76
TXG Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TXG is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a 10X Genomics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.1912.57
52 wk Range
6.7824.76
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TXG Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a 10X Genomics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
15.00
Upside
+22.25%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- 10X Genomics Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - 10X Genomics Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- 10X Genomics Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - 10X Genomics Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - 10x Genomics to acquire Scale Biosciences for single cell tech
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
10X Genomics Inc Company Profile
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
10X Genomics Inc SWOT Analysis
Genomics Pionee | 10X Genomics leads in single-cell and spatial genomics, offering innovative tools for oncology, immunology, and neuroscience research |
Navigating Headwinds | Explore how 10X Genomics is addressing challenges in instrument sales and capital expenditure softness while maintaining strong consumables demand |
Strategic Realignment | Learn about the company's sales reorganization and leadership changes aimed at driving growth and improving operational efficiency |
Future Prospects | Analyst price targets range from $19 to $35, with expectations of potential recovery and growth opportunities in the evolving genomics market |
10X Genomics Inc Earnings Call Summary for Q4/2024
- Q4 2024 EPS of -$0.40 missed forecast; revenue of $165M beat expectations but declined 10% YoY; stock fell 6.75% after hours
- Gross margin improved to 67%; company maintains strong liquidity with $393.4M cash, more cash than debt on balance sheet
- 2025 revenue guidance of $610-630M (0-3% growth); focus on biopharma and large-scale single-cell projects
- New product launches expected to drive growth; potential $10-15M revenue impact from NIH budget cuts
- Commercial transformation ongoing; company aims to democratize single-cell analysis amid competitive market pressures
Last Updated: 12/02/2025, 23:44
Read Full TranscriptCompare TXG to Peers and Sector
Metrics to compare | TXG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTXGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.1x | −3.1x | −0.5x | |
PEG Ratio | −0.28 | −0.34 | 0.00 | |
Price/Book | 2.0x | 1.4x | 2.6x | |
Price / LTM Sales | 2.4x | 1.9x | 3.3x | |
Upside (Analyst Target) | 22.1% | 24.3% | 43.3% | |
Fair Value Upside | Unlock | 20.3% | 6.9% | Unlock |
Analyst Ratings
6 Buy
9 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 15.00
(+22.25% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
0.28 / -0.37
Revenue / Forecast
172.90M / 139.40M
People Also Watch
FAQ
What Stock Exchange Does 10X Genomics Trade On?
10X Genomics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for 10X Genomics?
The stock symbol for 10X Genomics is "TXG."
What Is the 10X Genomics Market Cap?
As of today, 10X Genomics market cap is 1.56B.
What Is 10X Genomics's Earnings Per Share (TTM)?
The 10X Genomics EPS (TTM) is -0.69.
When Is the Next 10X Genomics Earnings Date?
10X Genomics will release its next earnings report on 28 Oct 2025.
From a Technical Analysis Perspective, Is TXG a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has 10X Genomics Stock Split?
10X Genomics has split 0 times.
How Many Employees Does 10X Genomics Have?
10X Genomics has 1306 employees.
What is the current trading status of 10X Genomics (TXG)?
As of 11 Aug 2025, 10X Genomics (TXG) is trading at a price of 12.27, with a previous close of 12.29. The stock has fluctuated within a day range of 12.19 to 12.57, while its 52-week range spans from 6.78 to 24.76.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.